ImmuPharma plc (LON:IMM – Get Free Report) shares were up 8.1% on Tuesday . The company traded as high as GBX 4.05 and last traded at GBX 4.05. Approximately 2,067,688 shares were traded during mid-day trading, a decline of 27% from the average daily volume of 2,824,305 shares. The stock had previously closed at GBX 3.75.
ImmuPharma Trading Up 8.1%
The firm has a 50-day moving average price of GBX 4.25 and a 200-day moving average price of GBX 5.56. The company has a market capitalization of £25.27 million, a price-to-earnings ratio of -10.95 and a beta of 3.02.
ImmuPharma (LON:IMM – Get Free Report) last announced its quarterly earnings data on Wednesday, May 27th. The company reported GBX (0.37) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 1,397.44%. Equities research analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
- Abivax: Wall Street Catches Up to the Data
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
